Iterum Therapeutics Set to Shine at Global Investment Conference
Iterum Therapeutics plc (Nasdaq: ITRM), headquartered in Dublin, Ireland, and Chicago, is a leading clinical-stage pharmaceutical company dedicated to developing next-generation oral antibiotics. These groundbreaking treatments are designed to combat infections caused by multi-drug resistant pathogens in community settings. Recently, CEO Corey Fishman announced their participation in the 26th Annual H.C. Wainwright Global Investment Conference, sharing some exciting updates.
Conference Details and Presentation Schedule
This esteemed conference will be held from September 9 to September 11, 2024, at the luxurious Lotte New York Palace Hotel. Iterum is set to present on September 10 at 8:30 am ET, where they will outline their progress and future plans. On the same day, management will also be available for one-on-one meetings with interested investors.
Access and Availability
The H.C. Wainwright conference is intended for qualified investors. For those who cannot attend in person, a webcast of the presentation will be available shortly after it concludes on Iterum’s website in the Events & Presentations section.
Dedication to Fighting Antibiotic Resistance
Iterum Therapeutics is dedicated to tackling the growing global issue of multi-drug resistant pathogens. The company is actively working on innovative anti-infectives aimed at significantly enhancing health outcomes for patients facing serious infections. Their flagship product, sulopenem, is a novel penem anti-infective available in both oral and intravenous forms.
Promising Product Pipeline
Sulopenem has demonstrated strong in vitro activity against a variety of gram-negative, gram-positive, and anaerobic bacteria that are resistant to current antibiotics. Iterum is currently navigating the regulatory landscape, having submitted a New Drug Application (NDA) for oral sulopenem to treat uncomplicated urinary tract infections in adult women. This application has been accepted for review by the U.S. Food and Drug Administration (FDA).
Regulatory Designations and Recognitions
Due to its potential, sulopenem has been awarded both Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA for seven different indications. These designations underscore the urgency of combating antibiotic resistance while also expediting the development and review of drugs that show promise in treating serious infections.
Contact Information for Interested Parties
Investors or others interested in connecting with Iterum Therapeutics can reach out to Judy Matthews, the Chief Financial Officer, at 312-778-6073 or via email. The company welcomes inquiries as it seeks to engage with stakeholders and provide further insights into its innovative work in the pharmaceutical sector.
Frequently Asked Questions
What is the focus of Iterum Therapeutics?
Iterum Therapeutics primarily focuses on developing new oral antibiotics to combat multi-drug resistant infections.
When will Iterum present at the H.C. Wainwright Conference?
Iterum's presentation is scheduled for September 10, 2024, at 8:30 am ET.
What product is Iterum currently working on?
Iterum is advancing sulopenem, a novel anti-infective candidate designed to treat infections resistant to other antibiotics.
What regulatory designations has sulopenem received?
Sulopenem has received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA.
Who can attend the H.C. Wainwright Conference?
The conference is open to qualified investors interested in the latest advancements in the pharmaceutical industry.
